Treatment and outcomes for early non-small-cell lung cancer: a retrospective analysis of a Portuguese hospital database

• Type: Article in International Scientific Journal
• Date: 2021

Authors

Soares, M (Author) Other; Antunes, L (Author) Other; Redondo, P (Author) Other; Borges, M (Author) Other; Hermans, R (Author) Other; Patel, D (Author) Other; Grimson, F (Author) Other; Munro, R (Author) Other; Chaib, C (Author) Other; Lacoin, L (Author) Other; Daumont, M (Author) Other; Penrod, JR (Author) Other; O'Donnell, JC (Author) Other; Bento, MJ (Author) Other; Gonçalves F (Author) FMUP

Journal

The Journal is awaiting validation by the Administrative Services.

Title: LUNG CANCER MANAGEMENT

Vol. 10

ISSN: 1758-1966

Indexing

ISI Web of Knowledge - 1 Citation

Scopus - 1 Citation

Other information

Authenticus ID: P-00T-KM2

DOI: 10.2217/lmt-2020-0028

Abstract (EN): Aim: This observational study evaluated treatment patterns and survival for patients with stage I-IIIA non-small-cell lung cancer (NSCLC). Materials & methods: Adults newly diagnosed with NSCLC in 2012-2016 at IPO-Porto hospital were included. Treatment data were available for patients diagnosed in 2015-2016. Results: 495 patients were included (median age: 67 years). The most common treatments were surgery alone or with another therapy (stage I: 66%) and systemic anticancer therapy plus radiotherapy (stage II: 54%; stage IIIA: 59%). One-year OS (95% CI) for patients with stage I, II and IIIA NSCLC (diagnosed 2012-2016) were 92% (88-96), 71% (62-82) and 69% (63-75), respectively; one-year OS (95% CI) for treated patients with stage I-II or stage IIIA NSCLC (diagnosed 2015-2016) were 89% (81-97) and 86% (75-98) for non-squamous cell and 76% (60-95) and 49% (34-70) for squamous cell NSCLC. Conclusion: Treatment advances are strongly needed for stage I-IIIA NSCLC, especially for patients with squamous cell histology.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 7